Biotech Values

[masterlongevity]

companies without enough cash to bring their products to market.

Stock Product Stage Comments ----- --------------- --------------------- ----------------------------- NTII Viprinex Phase 3 Interim analysis January '09. Stroke Drug, high chance of failure. BPAX Libigel Phase 3 ~2010 Submit Adequate Safety? EPIX Vasovist PDUFA 12/30/08 FDA initial rejected saying 2 more studies needed. Allowed reread company states results very positive. Looking to sell outright on approval. RPRX Proellex Phase 3 Uterine fibroids

ELAN bapineuzimab ph 3 no data expected until late 2010. enough cash to last only until mid 2010